Logo image of XAIR

BEYOND AIR INC (XAIR) Stock Fundamental Analysis

NASDAQ:XAIR - US08862L1035 - Common Stock

2.2083 USD
-0.07 (-3.14%)
Last: 8/26/2025, 11:39:07 AM
Fundamental Rating

3

Taking everything into account, XAIR scores 3 out of 10 in our fundamental rating. XAIR was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of XAIR have multiple concerns. XAIR is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XAIR has reported negative net income.
XAIR had a negative operating cash flow in the past year.
In the past 5 years XAIR always reported negative net income.
In the past 5 years XAIR always reported negative operating cash flow.
XAIR Yearly Net Income VS EBIT VS OCF VS FCFXAIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of XAIR (-155.10%) is worse than 89.73% of its industry peers.
XAIR has a worse Return On Equity (-343.26%) than 80.00% of its industry peers.
Industry RankSector Rank
ROA -155.1%
ROE -343.26%
ROIC N/A
ROA(3y)-114.02%
ROA(5y)-88.4%
ROE(3y)-243.66%
ROE(5y)-173.09%
ROIC(3y)N/A
ROIC(5y)N/A
XAIR Yearly ROA, ROE, ROICXAIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400 -600 -800 -1K

1.3 Margins

XAIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XAIR Yearly Profit, Operating, Gross MarginsXAIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

3

2. Health

2.1 Basic Checks

XAIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XAIR has been increased compared to 1 year ago.
XAIR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XAIR has a worse debt to assets ratio.
XAIR Yearly Shares OutstandingXAIR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
XAIR Yearly Total Debt VS Total AssetsXAIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -17.23, we must say that XAIR is in the distress zone and has some risk of bankruptcy.
XAIR's Altman-Z score of -17.23 is on the low side compared to the rest of the industry. XAIR is outperformed by 88.11% of its industry peers.
XAIR has a Debt/Equity ratio of 0.68. This is a neutral value indicating XAIR is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.68, XAIR is not doing good in the industry: 70.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -17.23
ROIC/WACCN/A
WACC8.16%
XAIR Yearly LT Debt VS Equity VS FCFXAIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

XAIR has a Current Ratio of 3.20. This indicates that XAIR is financially healthy and has no problem in meeting its short term obligations.
XAIR has a better Current ratio (3.20) than 61.08% of its industry peers.
A Quick Ratio of 2.72 indicates that XAIR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.72, XAIR is doing good in the industry, outperforming 65.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.72
XAIR Yearly Current Assets VS Current LiabilitesXAIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

XAIR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -303.05%.
XAIR shows a strong growth in Revenue. In the last year, the Revenue has grown by 219.67%.
The Revenue has been growing by 21.66% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-303.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
Revenue 1Y (TTM)219.67%
Revenue growth 3YN/A
Revenue growth 5Y21.66%
Sales Q2Q%157.69%

3.2 Future

Based on estimates for the next years, XAIR will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.51% on average per year.
Based on estimates for the next years, XAIR will show a very strong growth in Revenue. The Revenue will grow by 80.86% on average per year.
EPS Next Y18.45%
EPS Next 2Y24.86%
EPS Next 3Y27.73%
EPS Next 5Y16.51%
Revenue Next Year238.81%
Revenue Next 2Y182.87%
Revenue Next 3Y125.33%
Revenue Next 5Y80.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XAIR Yearly Revenue VS EstimatesXAIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
XAIR Yearly EPS VS EstimatesXAIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XAIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XAIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XAIR Price Earnings VS Forward Price EarningsXAIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XAIR Per share dataXAIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

XAIR's earnings are expected to grow with 27.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.86%
EPS Next 3Y27.73%

More info and screens

0

5. Dividend

5.1 Amount

XAIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEYOND AIR INC

NASDAQ:XAIR (8/26/2025, 11:39:07 AM)

2.2083

-0.07 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners20.86%
Inst Owner Change-41.79%
Ins Owners13.38%
Ins Owner Change11.78%
Market Cap11.55M
Analysts80
Price Target11.42 (417.14%)
Short Float %N/A
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.88%
Min EPS beat(2)8.09%
Max EPS beat(2)27.68%
EPS beat(4)4
Avg EPS beat(4)13.93%
Min EPS beat(4)3.34%
Max EPS beat(4)27.68%
EPS beat(8)7
Avg EPS beat(8)10.97%
EPS beat(12)8
Avg EPS beat(12)5.18%
EPS beat(16)8
Avg EPS beat(16)-11.58%
Revenue beat(2)1
Avg Revenue beat(2)-2.96%
Min Revenue beat(2)-18.64%
Max Revenue beat(2)12.72%
Revenue beat(4)1
Avg Revenue beat(4)-11.74%
Min Revenue beat(4)-24.93%
Max Revenue beat(4)12.72%
Revenue beat(8)1
Avg Revenue beat(8)-29.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-75.11%
PT rev (3m)397.78%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)-1373.68%
EPS NY rev (1m)-1577.45%
EPS NY rev (3m)-1043.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.25%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-5.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.12
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-6.61
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-8.43
FCFYN/A
OCF(TTM)-7.31
OCFYN/A
SpS0.71
BVpS2.6
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.1%
ROE -343.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-114.02%
ROA(5y)-88.4%
ROE(3y)-243.66%
ROE(5y)-173.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 183.61%
Cap/Sales 158.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.72
Altman-Z -17.23
F-Score3
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)311.89%
Cap/Depr(5y)350.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-303.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
EPS Next Y18.45%
EPS Next 2Y24.86%
EPS Next 3Y27.73%
EPS Next 5Y16.51%
Revenue 1Y (TTM)219.67%
Revenue growth 3YN/A
Revenue growth 5Y21.66%
Sales Q2Q%157.69%
Revenue Next Year238.81%
Revenue Next 2Y182.87%
Revenue Next 3Y125.33%
Revenue Next 5Y80.86%
EBIT growth 1Y29.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.77%
OCF growth 3YN/A
OCF growth 5YN/A